Volume : 11, Issue : 01, January – 2024
Title:
LIPOSPHERES DRUG DELIVERY SYSTEM OF ANTIDIABETIC DRUGS: A REVIEW
Authors :
Shreyash Shriniwas Kambagouniwar*, Dr. Pankaj M. Pimpalshende, Dr. Satish B. Kosalge
Abstract :
Diabetes is a long-term metabolic disease caused by insufficient insulin that is characterized by elevated blood sugar, changed metabolism of fats, proteins, and carbohydrates, and a higher risk of cardiovascular problems. Anti-diabetic medications are a great fit for liposphere drug delivery systems because to their drawbacks, which include inconsistent bioavailability, substantial first pass metabolism, and more frequent administration. Compared to emulsions, liposomes, and microspheres, the lipospheres carrier system offers a number of benefits, including improved physical stability, reduced ingredient costs, ease of preparation and scaling up, high dispersability in an aqueous medium, high entrapment of hydrophobic drugs, controlled particle size, and extended release of entrapped drug. This review article provides a thorough understanding of diabetes, including its causes, classifications, and current treatment options. It further expands on the topic by discussing lipospheres as innovative drug delivery systems and their historical implications for the administration of anti-diabetic medications.
Keywords: Liposphere, Diabetes, Novel drug delivery system, Antidiabetic drugs
Cite This Article:
Please cite this article in press Shreyash Shriniwas Kambagouniwar et al., Lipospheres Drug Delivery System Of Antidiabetic Drugs: A Review, Indo Am. J. P. Sci, 2024; 11 (01).
Number of Downloads : 10
References:
1. Maiti R, Jana D, Das UK, Ghosh D. Antidiabetic effect of aqueous extract of seed of Tamarindusindica in streptozotocin induced diabetic rats. J Ethnopharmaco 2004; 92: 85-91.
2. WadkarKA,Magdum CS, Patil SS, NaikwadeNS.Antidiabetic potential and Indian medicinal plants. J Herbal Med Toxicol 2008; 2: 45-50.
3. Patlak, M. New Weapons to Combat an Ancient Disease: Treating Diabetes.FASEB J. 2002, 16 (14), 1853.
4. World Health Organization.Global Report on Diabetes.2016, 88
5. Jun SK, Yoon YW.A new look at viruses in Type 1 diabetes, Diabetes/Metabolism Research and Reviews.2002; 19:8-31.
6. Newman B., Selby J. V., King M. C., Slemenda C., Fabsitz, R., Friedman, G. D. Concordance for type 2 (non-insulindependent) diabetes mellitus in male twins.Diabetology 1987; 30: 763–768. Doi: 10.1007/BF00275741.
7. Bellamy L., Casas J. P. Hingorani, A. D. Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009; 373: 1773–1779. Doi: 10.1016/S0140-6736(09)60731-5
8. Piero, M. N. Diabetes Mellitus – a Devastating Metabolic Disorder.Asian J. Biomed. Pharm. Sci. 2015, 4 (40), 1–7.
9. Mohan V, Pradeepa R. Epidemiology of diabetes in different regions of India.2009; 22:1-18.
10. Singh N, Kesherwani R, Tiwari AK, Patel DK. A review on diabetes mellitus.ThePharma Innovation.2016 Jul 1;5(7, Part A):36.
11. Wilcox G. Insulin and insulin resistance.Clinical biochemist reviews. 2005 May;26(2):19.
12. Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Annals of internal medicine. 2016 Jun 7;164(11):740-51.
13. Dixon JB, Le Roux CW, Rubino F, Zimmet P. Bariatric surgery for type 2 diabetes.The Lancet. 2012 Jun 16;379(9833):2300-11.
14. Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W, Schipper H, Gander R. Clinical control of diabetes by the artificial pancreas. Diabetes. 1974 May 1;23(5):397-404.
15. Marfil-Garza BA, Imes S, Verhoeff K, Hefler J, Lam A, Dajani K, Anderson B, O’Gorman D, Kin T, Bigam D, Senior PA. Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada.The lancet Diabetes & endocrinology. 2022 Jul 1;10(7):519-32.
16. Rathor M, Gupta MK, Sharma V. A review on oral liposphere of candesartan cilexetil. Int J Pharma Bio Sci Archive, 2018; 6(1): 01-04.
17. Ganesan V, Allimalarkodi S. Liposphere: A versatile drug delivery system-an over view. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2015 Jul 1;6(4):1753-62.
18. Domb AJ. Liposphere carriers of vaccines.Comparative Immunology, Microbiology and Infectious Diseases.1995;3(18):IV.
19. Elgart A, Cherniakov I, Aldouby Y, Domb AJ, Hoffman A. Lipospheres and pro-nanolipospheres for delivery of poorly water soluble compounds. Chemistry and Physics of Lipids. 2012 May 1;165(4):438-53.
20. Dudala TB, Yalavarthi PR, Vadlamudi HC, Thanniru J, Yaga G, Mudumala NL, Pasupati VK.A perspective overview on lipospheres as lipid carrier systems.International journal of pharmaceutical investigation. 2014 Oct;4(4):149.
21. Kumar A, Jain UK, Patel A. Formulation development and evaluation of liposphere of poor water soluble drug for Hyperlipidemia.Journal of Drug Delivery and Therapeutics. 2021 Mar 15;11(2):23-30.
22. Nastruzzi C, editor. Lipospheres in drug targets and delivery: approaches, methods, and applications. CRC Press; 2004 Nov 29.
23. Morels S.,Gasco M.R., Cavalli R. Incorporation in lipospheres of [D – TrP – 6] LHRH. Int. J. Pharm., 1994; 105: R1–R3.
24. Ahirwar Ramesh, Mr. ChaurasiaAshish, Dr. Nigam Vijay, Dr. Chourasiyakumar Anil, KankaneMuskan, AdhikariPooja. Liposphere: A Comprehensive Review. International Journal of Pharmaceutical Research and Applications, 2023 Jan-Feb,Volume 8, Issue 1, pp: 1151-1161
25. Rawat M., Saraf S. Liposphere: Emerging carriers in delivery of proteins and peptides.Int.J. Pharm. Sci. and Nanotechnol, 2008;1: 207 – 214.
26. CortesiR.Preparation of liposomes by reverse-phase evaporation using alternative organic solvents, J. Microencapsul 1999;16: 251-256.
27. Gander B, johansen P, Nam-Tran H, Merkle HP. Thermodynamic approach to protein microencapsulation into poly (D,L-lactide) by spray drying. Int J Pharm 1996;129:51-61.
28. Attama AA, Okafor CE, Builders PF, Okorie O. Formulation and in vitro evaluation of a PEGylated microscopic lipospheres delivery system for ceftriaxone sodium.Drug delivery. 2009 Nov 1;16(8):448-57.
29. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci, 2006; 29(3-4): 278-87.
30. Rainer HM, Karsten M, Sven G. Solid lipid nanoparticles (SLN) for controlled drug delivery: A review of the state of the art. Euro J Pharm Biopharma, 2000; 5(1): 161-77.
31. Larsson K. Cubic lipid-water phases: Structures and biomembrane aspects. J PhysChem, 1989; 93 (21): 7304–14.
32. Rafiee MH, Rasool BK, Haider M, Anbar HS.Oral pioglitazone HCl-loaded solid lipid microparticles: Formulation design and bioactivity studies.Journal of Applied Pharmaceutical Science. 2023 Feb 5;13(2):161-74
33. Rasul A, Maheen S, Khan HU, Rasool M, Shah S, Abbas G, Afzal K, Tariq F, Shahzadi I, Asad MH. Formulation, Optimization, In Vitro and In Vivo Evaluation of Saxagliptin-Loaded Lipospheres for an Improved Pharmacokinetic Behavior. BioMed Research International. 2021 Oct 20;2021:1-7.
34. Nnamani PO, Ibezim EC, Adikwu MU, Attama AA. Sustained-Release Glibenclamide-Loaded Solid Lipid Microparticles from Micellar Solutions of Homolipids.Journal of Pharmaceutical Innovation.2022 Sep 1:1-1.
35. Masoomzadeh S, Maghsoodi M. Different ways to enhance the permeability, lipophilicity, and bioavailability of the antidiabetic drug, Metformin. Trends in Pharmaceutical Sciences. 2022 Jun 1;8(2):69-74.
36. Ilyas U, Asif M, Wang M, Altaf R, Zafar H, Faran Ashraf Baig MM, Paiva-Santos AC, Abbas M. Nanostructured lipid carrier-based delivery of pioglitazone for treatment of type 2 diabetes.Frontiers in Pharmacology. 2022 Jul 12; 13:934156.
37. Dangi AA, Sorathiya D, Sheth NR, Bagthariya SH, Solanki SM, Chavda A. Preparation and characteristic of solid lipid nanoparticles loaded with Rosiglitazone Maleate. Inventi Rapid: NDDS. 2011; 3.